JMJheem D. Medh

Jheem D. Medh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jheem D. Medh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phosphatidylcholine-Mediated Aqueous Diffusion of Cellular Cholesterol Down-Regulates the ABCA1 Transporter in Human Skin Fibroblasts

    by David Akopian, Ryoko L. Kawashima, Jheem D. Medh

    ATP-binding cassette protein A1 (ABCA1) is a cholesterol transporter that contributes to the active transport/removal of excess cellular cholesterol. ABCA1 expression is up-regulated when cells accumulate cholesterol. Aims: The purpose of this study was to determine any correlation between extracellular phospholipid levels and ABCA1 expression and function. Methodology: Human foreskin fibroblasts were incubated with cholesterol alone or cholesterol and phosphatidylcholine. Total RNA was isolated and subjected to end-point RT-PCR to compare ABCA1 transcript levels. Cell lysates were subjected to Western blot analysis to compare ABCA1 protein levels. Cells were loaded with radiolabeled cholesterol and cellular cholesterol efflux was measured in the presence and absence of apoE, a cholesterol acceptor. ApoE-dependent efflux was calculated as a measure of ABCA1-mediated efflux. Results: Here we show that incubation of cholesterol-loaded human skin fibroblasts with L--phosphatidylcholine (PC) decreases ABCA1 mRNA and protein levels by 93% and 57%, respectively, compared to cells loaded with cholesterol alone. Similarly, PC treatment results in a 25% reduction in ABCG1 mRNA levels compared to cells treated with cholesterol alone, but there is no change in SR-BI transcript levels. Subsequent incubation of phospholipid-treated cells with a cholesterol acceptor such as apoE for 24 hours shows a 65% reduction in ABCA1-mediated cholesterol efflux compared to efflux in cells not treated with PC. During the lipid treatment itself, there is a 2.7-fold greater loss of cholesterol from PC treated cells compared to cells treated with cholesterol alone. Measurement of cholesterol in cellular lipid extracts reveals that cells incubated in the presence of phosphatidylcholine are significantly depleted of cholesterol having only 20% of the cholesterol compared to cells loaded with cholesterol alone. Conclusion: Thus, phosphatidylcholine facilitates removal of cellular cholesterol, thereby negating the cholesterol-dependent induction of ABCA1 message, protein and function.


  • Open Access

    Regulation of Translational Efficiency by Disparate 5′‐UTRs of PPARγ Splice Variants

    by Shawn McClelland, Roopali Shrivastava, Jheem D Medh

    The PPAR‐γ gene encodes for at least 7 unique transcripts due to alternative splicing of five exons in the 5′‐untranslated region (UTR). The translated region is encoded by exons 1–6, which are identical in all isoforms. This study investigated the role of the 5′‐UTR in regulating the efficiency with which the message is translated to protein. A coupled in vitro transcription‐translation assay demonstrated that PPAR‐γ1, ‐γ2, and ‐γ5 are efficiently translated, whereas PPAR‐γ4 and ‐γ7 are poorly translated. An in vivo reporter gene assay using each 5′‐UTR upstream of the firefly luciferase gene showed that the 5′‐UTRs for PPAR‐γ1, ‐γ2, and ‐γ4 enhanced translation, whereas the 5′‐UTRs for PPAR‐γ5 and ‐γ7 inhibited translation. Models of RNA secondary structure, obtained by the mfold software, were used to explain the mechanism of regulation by each 5′‐UTR. In general, it was found that the translational efficiency was inversely correlated with the stability of the mRNA secondary structure, the presence of base‐pairing in the consensus Kozak sequence, the number of start codons in the 5′‐UTR, and the length of the 5′‐UTR. A better understanding of posttranscriptional regulation of translation will allow modulation of protein levels without altering transcription.


  • Genetics and molecular biology: phospholipid transfer protein in atherogenesis

    by David Akopian, Jheem D Medh

    Human phospholipid transfer protein (PLTP) is a 476 amino acid secreted protein that catalyzes the transfer of phospholipids and vitamin E between lipoprotein particles [1,2•,3•]. PLTP plays a key role in the formation and homeostasis of high-density lipoprotein (HDL) particles; it transfers phospholipids from very-low-density lipoprotein (VLDL) surface remnants to HDL particles, it facilitates the interconversion of HDL subclasses, and generates lipid-poor preβ-HDL particles. PLTP is synthesized by various cell types but its primary function is in the plasma where it is transported in association with apolipoproteins. Plasma PLTP exists in two forms: a high activity form that co-purifies with apolipoprotein (apo) E and a low activity form associated with apoA-I. It was reported recently that both apoE and apoA-IV can activate PLTP [4•]. PLTP has both pro- and antiatherogenic characteristics. Preβ-HDL particles, a major product of PLTP catalysis, are required as acceptors for the atheroprotective cholesterol efflux pathway [5]. Studies in human subjects and genetically engineered mice indicate that plasma PLTP activity is proatherogenic. Human subjects with cardiovascular disease (CVD) have higher plasma PLTP activity compared with normal subjects [6]. Similarly, obesity and type 2 diabetes are coincident with high PLTP activity [7,8]. Overexpression of PLTP in LDLR–/– mice results in a reduction in plasma HDL and apoA-I levels, an increase in VLDL secretion, and an increase in susceptibility to atherosclerosis despite lower apoB-containing lipoproteins [9]. Plasma HDL levels are also decreased in PLTP knock-out mice [10]. These mice, however, show a dramatic reduction in apoB synthesis and a significantly reduced susceptibility to diet-induced atherosclerosis. Several recent studies were aimed at better understanding the pro- and antiatherogenic mechanisms of PLTP activity. The current consensus is that systemic or plasma PLTP is proatherogenic, but macrophage PLTP is atheroprotective. Support for a proatherogenic role of plasma PLTP was obtained from a recent study investigating the relationship between PLTP activity and various inflammatory markers in humans with CVD [11•]. PLTP activity was positively and independently correlated with the main inflammatory marker C-reactive protein (CRP). Positive association of PLTP was also seen with other inflammation markers including serum amyloid A protein (SAA) and interleukin-6. Cardiovascular risk factors including body mass index, insulin resistance, apoE (VLDL), and apoB levels were directly correlated with PLTP activity as well as with CRP and SAA levels. These results clearly indicate that PLTP activity is important in both inflammation and CVD. Another marker of CVD, coronary artery intima-media thickness (IMT), was found to be independently associated with PLTP activity in diabetics, but not in nondiabetic subjects [12•]. ApoE may play a key role in the pathophysiological effects of PLTP. In diabetic subjects, the level of active plasma PLTP appeared to be modulated by apoE [13•]. PLTP activity showed a strong positive correlation with plasma apoB and apoE levels, but was inversely related to apoA-I levels [13•]. As the active form of PLTP associates with apoE and the inactive form with apoA-I, these results suggest that apoE may be capable of converting inactive PLTP into the active form. The relationship between apoE and PLTP was further investigated in diabetic subjects of the Diabetes Atorvastatin Lipid Intervention (DALI) study [14•]. Atorvastatin treatment significantly reduced plasma apoE levels with a concomitant decrease in plasma PLTP activity. In a multivariate model, the change in apoE levels was the only determinant of the reduction in PLTP activity. Thus, apoE levels appear to modulate plasma PLTP activity. The main function of PLTP is to modify and modulate HDL levels. Thus, plasma apoA-I and HDL levels are reduced in both PLTP over-expressing transgenic mice and in PLTP knock-out mice [9,10].


  • Open Access

    Simultaneous Isolation of Total Cellular Lipids and RNA from Cultured Cells

    by David Akopian, Jheem D. Medh

    Lipid biochemists often need to analyze total cellular lipids as well as cellular messenger RNA (mRNA) levels. Conventionally, different cell samples are used for extraction of each class of biomolecule. Here, we describe a procedure for the simulta- neous isolation of both total cellular lipids and total RNA from the same sample. The method is based on the fact that mild organic solvents efficiently extract lipids but do not disrupt/degrade cellular RNA. This procedure not only reduces the time and expense of analysis, but also allows a direct inves- tigation of any correlation between lipid and transcript levels. While this method has only been applied in fibro- blasts, prior delipidation of samples may be useful for extraction of nucleic